TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ACS defined as a new pulmonary infiltrate involving at least one segment of the lung on a chest x-ray or chest CT scan with 2 or more of the following: chest pain, tachypnea, dyspnea, cough, hypoxemia, or body temperature greater than or equal to 38.0 degrees Celsius~* Hemoglobin electrophoresis confirming HbSS, SC, or B0 (historical records sufficient)~* Age greater than or equal to 18~Exclusion Criteria:~* Any absolute contraindication to heparin~* Platelet count less than 50 per microliter (current admission)~* Historical diagnosis of moyamoya disease as documented in medical records~* Historical diagnosis of proliferative retinopathy as documented in medical records~* Current participation in a chronic exchange transfusion program~* Underlying hypercoagulable disorder other than sickle cell disease~* Currently receiving therappeutic anticoagulation~* Currently receiving antiplatelet agents~* Currently receiving estrogen containing oral contraceptives~* Chest CT scan documented PE performed as standard of care prior to study enrollment (current admission)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unfractionated heparin (Type: EXPERIMENTAL): Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
- Standard of care (Type: NO_INTERVENTION): Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Markers of Pubertal Suppression During Therapy for Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age: 3 to 9 years old, inclusive~* Diagnosis of Central Precocious or Rapidly Progressive Puberty~* Bone Age more than 1 year advanced (obtained within 6 months of screening) AND~* Breasts Tanner II or greater AND~* One of the following:~* Random LH \> 1 mIU/mL~* Leuprolide-stimulated LH \> 4 mIU/mL~* Random estradiol \> 20 pg/mL~* Leuprolide-stimulated 24 hour estradiol \>20 pg/mL~* Naïve to GnRHa therapy~* Approved to receive Supprelin LA® therapy~* Have an acceptable surrogate capable of giving consent on the subject's behalf.~Exclusion Criteria:~* Previous GnRHa therapy~* Presence of peripheral precocious puberty including CAH

- Gender: FEMALE
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Children with Central Precocious Puberty (Type: None): Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria~2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)~3. Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior~4. A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living~5. Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf~6. Subjects who are deemed to be medically appropriate for study participation by the principal investigator~7. Participants who agree to use a medically acceptable and effective birth control method~Exclusion Criteria:~1. Subjects with dementia or other memory impairment not due to probable AD.~2. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function.~3. Subjects with agitation caused by acute intoxication.~4. Subjects with significant risk of suicide or homicide per the investigator's assessment.~5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location.~6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia.~7. Subjects with laboratory or ECG abnormalities.~8. Subjects who have received an investigational drug within 30 days prior to Screening.~9. Subjects who are currently suffering from substance abuse.~10. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1- 40 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 40 Micrograms Dexmedetomidine
- Cohort 2- 60 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 60 Micrograms Dexmedetomidine
- Placebo (Type: PLACEBO_COMPARATOR): Sublingual Placebo film

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female Patients aged 12 to 50 years with a diagnosis of asthma for at least 6 months before screening~* Baseline FEV1 of 60% to \>100% of predicted~* Demonstrate a decrease in FEV1 of 15% or greater from baseline after standardized stepped exercise challenge testing~* Taking a constant dose of low-medium dose inhaled steroids for at least 30 days before screening of either:~  1. fluticasone, 88 - 440 mcg/d via MDI or 100 to 500 mcg/d via DPI~ 2. beclomethasone HFA 80 to 480 mcg/day~ 3. budesonide DPI 180 to 1200 mcg/ d~ 4. flunisolide 500 to 2000 mcg/d~ 5. flunisolide HFA 320 to 640 mcg/d~ 6. mometasone 200 to 800 mcg/d~ 7. triamcinolone acetonide 300 to 1500 mcg/ d~Exclusion Criteria:~* Patients already on LABAs, systemic corticosteroids, or other combination inhaled steroids/LABA medications.~* Patients not able to safely complete an exercise challenge due to physical constraints outside of their respiratory status.~* Patients who are pregnant or plan to become pregnant during the study period.~* Patients with a history of hypersensitivity reaction to either formoterol or budesonide.~* Patients with any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study.~* Patients with planned hospitalization during the study~* Current Smokers or those with a history of 10 pack years of tobacco use or more.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide/Formoterol first (Type: EXPERIMENTAL): This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
- Budesonide first (Type: ACTIVE_COMPARATOR): This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed pancreatic cancer~  * Locally advanced, metastatic, or recurrent disease~* Measurable or evaluable disease by physical exam, plain radiographs, CT scan, or MRI~* No brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy of 12 weeks or greater~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present)~* No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)~* Creatinine ≤ 2.0 mg/dL~* No chronic renal disease~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier-method contraception during and for ≥ 3 months after completion of study treatment~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix~* No uncontrolled diabetes~* No active uncontrolled infection~* No other severe and/or uncontrolled medical disease~* HIV negative~PRIOR CONCURRENT THERAPY:~* No prior therapy for metastatic disease~  * Prior fluorouracil as a radiosensitizer for adjuvant therapy after surgery or for locally advanced disease is permitted if local disease has recurred or progressed ≥ 3 months after completion of therapy or disease is present outside the radiation field~* At least 2 weeks since prior major surgery~* No concurrent grapefruit or grapefruit juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between the ages of 18 and 75 years~* Must be a patient undergoing screening or surveillance colonoscopy~* Must be able to understand and willing to sign an IRB-approved written informed consent document.~Exclusion Criteria:~* Inability to provide informed consent.~* Personal history of colorectal cancer (CRC)~* Personal history of colon surgery or colon resection~* Personal history of Inflammatory bowel disease~* Personal history of familial polyposis~* Current pregnancy~* Active GI bleeding~* Colonoscopy exams where the cecum cannot be reached (randomization will occur after cecum is reached).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Colonoscopy 6 minute withdrawal time (Type: ACTIVE_COMPARATOR): -Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
- Arm 2: Colonoscopy 9 minute withdrawal time (Type: EXPERIMENTAL): -Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
- Arm 3: Colonoscopy 12 minute withdrawal time (Type: EXPERIMENTAL): -Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed prostate cancer adenocarcinoma~* definitive radiotherapy for curative intent~* low or intermediate risk prostate cancer~* patient age ≥ 75 years~* given informed consent~Exclusion Criteria:~* chronic inflammatory bowel disease~* high risk prostate cancer~* lymph node or distant metastases~* unable to give informed consent

- Gender: MALE
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypofractionated radiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Test-and-treat for Influenza in Homeless Shelters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resident for 1 or more days at a participating shelter~* ≥2 ARI symptoms or acute cough alone~* Willing to take study medication~* Willing to comply with all study procedures, including weekly surveillance and repeat nasal swab at day 2/3 and day 5/6/7 post-treatment~* Able to provide written, informed consent and/or assent~Exclusion Criteria:~* Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration~* Inability to consent and/or comply with study protocol~* Individuals who have received oseltamivir or baloxavir within past 7 days for treatment of influenza~* Individuals with known hypersensitivity to baloxavir marboxil or oseltamivir~* Individuals with chronic kidney disease

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard influenza surveillance (Type: NO_INTERVENTION): Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
- Point-of-care molecular testing and treatment of influenza (Type: ACTIVE_COMPARATOR): Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A \& B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Method for Mydriasis in Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients aged 40 or older who are undergoing routine cataract surgery under topical anesthesia with monitored anesthesia care at the Wilmer Eye Institute with Dr. Fasika Woreta and her senior resident proficient at cataract surgery.~Exclusion Criteria:~* Need for general anesthesia~* Maximum pupillary dilation \<6.0mm at the pre-op clinic visit.~* Prior intra-ocular surgery~* Prior trauma~* Any pre-existing iris abnormalities including pupillary deformity, posterior synechiae, peripheral anterior synechiae, zonular dehiscence~* Pseudoexfoliation~* Allergy to any of the mydriasis agents~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Mydriasis (Type: EXPERIMENTAL): Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
- Intracameral Mydriasis (Type: EXPERIMENTAL): Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
- Topical + Intracameral mydriasis (Type: EXPERIMENTAL): Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Customized Contrast Media Dose Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for a CT of the Abdomen \& Pelvis with Contrast Material~Exclusion Criteria:~* Younger than 18~* Pregnant~* Contraindication of iodinated contrast material~* Contraindication to a bolus injection~* Indication for biphasic exam (arterial + venous phases)~* Diffuse hepatic disease~* Subjects weighing more than 300 pounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fixed dose (Type: ACTIVE_COMPARATOR): 100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
- Customized dose (Type: ACTIVE_COMPARATOR): 100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years of age or greater~* Intention to treat with vasopressor for diagnosis of septic shock~* Exclusion criteria not met~Exclusion Criteria:~* Emergent indication for surgery~* Patient possesses a terminal condition for which patient or medical decision maker has decided to de-escalate medical care (patients with Do Not Resuscitate order but for whom standard care is continued will not be excluded)~* Known allergy to phenylephrine or norepinephrine~* Treated with vasopressor \>12 hours for current episode of shock~* Preference of specific vasopressor agent by patient's provider~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phenylephrine (Type: ACTIVE_COMPARATOR): Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
- Norepinephrine (Type: ACTIVE_COMPARATOR): Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues